Forxiga's generics, advertised for off-label indications

By Lee, Hye-Kyung | translator Kim, Jung-Ju

23.09.11 12:14:39

가나다라 0

The MFDS took administrative action against Boryung and Aju Pharmaceutical's Dapagliflozin preparations.

With over 200 approved products, there is a high possibility that other pharmaceutical companies will also dispose of them

This is because it promoted indications such as chronic heart failure that are only found in the original product

Forxiga's generic development companies that promoted 'chronic heart failure, chronic kidney disease' in their drug advertisements were subject to administrative sanctions.

On August 18th and 22nd, the Ministry of Food and Drug Safety suspended Boryung and Aju Pharmaceuticals from advertising for products containing Dapagliflozin for three months, respectively. The objects of disposal are three items, including Boryung's Trudapa 10 mg (Dapagliflozin Bis L-proline), Trudapa M SR 10/500 mg (Dapagliflozin, Metformin), and Trudapa M SR 10/1000 mg (Dapagliflozin, metformin). and Aju Pharmaceutical's Daparil 5 mg (Dapagliflozin Propanediol Hydrate), Daparil 10 mg (Dapagliflozin Propanediol Hydrate), Daparil

Lee, Hye-Kyung(hgrace7@dailypharm.com)

If you want to see the full article, please JOIN US (click)